GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Whanin Pharm Co Ltd (XKRX:016580) » Definitions » Piotroski F-Score

Whanin Pharm Co (XKRX:016580) Piotroski F-Score : 5 (As of May. 24, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Whanin Pharm Co Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Whanin Pharm Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Whanin Pharm Co's Piotroski F-Score or its related term are showing as below:

XKRX:016580' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 7
Current: 5

During the past 13 years, the highest Piotroski F-Score of Whanin Pharm Co was 7. The lowest was 2. And the median was 5.


Whanin Pharm Co Piotroski F-Score Historical Data

The historical data trend for Whanin Pharm Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Whanin Pharm Co Piotroski F-Score Chart

Whanin Pharm Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 5.00 6.00 5.00 4.00

Whanin Pharm Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 4.00 4.00 4.00 5.00

Competitive Comparison of Whanin Pharm Co's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Whanin Pharm Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Whanin Pharm Co's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Whanin Pharm Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Whanin Pharm Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was 8744.997 + 6343.678 + 7567.148 + 9071.223 = ₩31,727 Mil.
Cash Flow from Operations was 2819.907 + 375.447 + 14229.641 + 3545.14 = ₩20,970 Mil.
Revenue was 57626.095 + 58841.217 + 58385.99 + 61610.033 = ₩236,463 Mil.
Gross Profit was 25799.258 + 25627.914 + 23811.092 + 24889.187 = ₩100,127 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(382343.031 + 386399.908 + 390699.295 + 401226.633 + 415529.99) / 5 = ₩395239.7714 Mil.
Total Assets at the begining of this year (Mar23) was ₩382,343 Mil.
Long-Term Debt & Capital Lease Obligation was ₩281 Mil.
Total Current Assets was ₩216,419 Mil.
Total Current Liabilities was ₩49,720 Mil.
Net Income was 5571.078 + 4760.804 + 5261.781 + 7118.499 = ₩22,712 Mil.

Revenue was 48571.854 + 49360.472 + 52156.827 + 55540.276 = ₩205,629 Mil.
Gross Profit was 24471.577 + 25613.33 + 23590.92 + 23922.349 = ₩97,598 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(355081.536 + 350635.025 + 358602.68 + 369374.561 + 382343.031) / 5 = ₩363207.3666 Mil.
Total Assets at the begining of last year (Mar22) was ₩355,082 Mil.
Long-Term Debt & Capital Lease Obligation was ₩83 Mil.
Total Current Assets was ₩206,497 Mil.
Total Current Liabilities was ₩41,623 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Whanin Pharm Co's current Net Income (TTM) was 31,727. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Whanin Pharm Co's current Cash Flow from Operations (TTM) was 20,970. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=31727.046/382343.031
=0.08298058

ROA (Last Year)=Net Income/Total Assets (Mar22)
=22712.162/355081.536
=0.06396323

Whanin Pharm Co's return on assets of this year was 0.08298058. Whanin Pharm Co's return on assets of last year was 0.06396323. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Whanin Pharm Co's current Net Income (TTM) was 31,727. Whanin Pharm Co's current Cash Flow from Operations (TTM) was 20,970. ==> 20,970 <= 31,727 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=280.661/395239.7714
=0.0007101

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=83.25/363207.3666
=0.00022921

Whanin Pharm Co's gearing of this year was 0.0007101. Whanin Pharm Co's gearing of last year was 0.00022921. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=216419.163/49719.66
=4.35278847

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=206496.761/41623.077
=4.96111234

Whanin Pharm Co's current ratio of this year was 4.35278847. Whanin Pharm Co's current ratio of last year was 4.96111234. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Whanin Pharm Co's number of shares in issue this year was 15.271. Whanin Pharm Co's number of shares in issue last year was 15.276. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=100127.451/236463.335
=0.42343753

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=97598.176/205629.429
=0.47463136

Whanin Pharm Co's gross margin of this year was 0.42343753. Whanin Pharm Co's gross margin of last year was 0.47463136. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=236463.335/382343.031
=0.6184586

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=205629.429/355081.536
=0.57910482

Whanin Pharm Co's asset turnover of this year was 0.6184586. Whanin Pharm Co's asset turnover of last year was 0.57910482. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+0+0+0+1+0+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Whanin Pharm Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Whanin Pharm Co  (XKRX:016580) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Whanin Pharm Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Whanin Pharm Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Whanin Pharm Co (XKRX:016580) Business Description

Traded in Other Exchanges
N/A
Address
84-1 Munjeong-dong, Songpa-gu, Seoul, KOR, 138-200
Whanin Pharm Co Ltd is a pharmaceutical company. The company develops, manufactures, markets, and sells the therapeutic products. It offers antibiotics, cardiovascular drugs, CNS stimulants, gastrointestinal drugs, multivitamins and other products. The company's products include Antiasthmatics; Antidepressants; Antipsychotics; Anxiolytics and hypnotics; and Antiepileptics.

Whanin Pharm Co (XKRX:016580) Headlines

No Headlines